State of New Jersey Common Pension Fund D Sells 13,955 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

State of New Jersey Common Pension Fund D lessened its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 26.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 39,474 shares of the company’s stock after selling 13,955 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Vaxcyte were worth $2,981,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in PCVX. Vanguard Group Inc. increased its position in shares of Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after buying an additional 1,284,883 shares during the period. RA Capital Management L.P. boosted its position in Vaxcyte by 4.0% during the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after acquiring an additional 312,500 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Vaxcyte by 9.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after acquiring an additional 692,492 shares during the period. Capital Research Global Investors raised its position in shares of Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after acquiring an additional 700,414 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after purchasing an additional 498,359 shares during the period. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PCVX. Jefferies Financial Group raised their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC lifted their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Leerink Partners boosted their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Finally, Bank of America lifted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Trading Down 0.2 %

Shares of PCVX stock opened at $116.54 on Thursday. The firm has a fifty day simple moving average of $87.76 and a two-hundred day simple moving average of $75.76. Vaxcyte, Inc. has a 12 month low of $44.20 and a 12 month high of $119.50. The firm has a market capitalization of $12.68 billion, a PE ratio of -27.23 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter in the prior year, the company earned ($0.70) EPS. On average, equities analysts predict that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.37, for a total value of $127,308.79. Following the transaction, the senior vice president now owns 30,826 shares in the company, valued at $2,354,181.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Vaxcyte news, COO Jim Wassil sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $111.93, for a total value of $1,119,300.00. Following the completion of the sale, the chief operating officer now directly owns 207,503 shares of the company’s stock, valued at approximately $23,225,810.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mikhail Eydelman sold 1,667 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the completion of the sale, the senior vice president now owns 30,826 shares of the company’s stock, valued at approximately $2,354,181.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,283 shares of company stock valued at $7,271,218. Corporate insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.